Group 1 - Johnson & Johnson's stock closed at $150.47, down 1.24%, underperforming the S&P 500's gain of 0.61% on the same day [1] - Over the past month, Johnson & Johnson's stock has decreased by 3.78%, compared to a 1.45% loss in the Medical sector and a 5.79% gain in the S&P 500 [1] Group 2 - The upcoming earnings disclosure is expected to show an EPS of $1.99, reflecting a 13.1% decline year-over-year, while revenue is projected at $22.54 billion, a 5.37% increase from the previous year [2] - For the full year, earnings are estimated at $9.93 per share and revenue at $88.84 billion, indicating a 0.1% increase in earnings but a 4.49% decrease in revenue compared to the prior year [3] Group 3 - Recent adjustments to analyst estimates for Johnson & Johnson are important as they reflect short-term business trends, with positive revisions indicating a favorable outlook on the company's health and profitability [4] - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), currently places Johnson & Johnson at 3 (Hold), with a steady EPS estimate over the past month [6] Group 4 - Johnson & Johnson has a Forward P/E ratio of 15.34, which is higher than the industry average of 14.51, and a PEG ratio of 2.71 compared to the industry's average of 1.49 [7] - The Large Cap Pharmaceuticals industry, which includes Johnson & Johnson, has a Zacks Industry Rank of 156, placing it in the bottom 38% of over 250 industries [8]

Core Viewpoint - Johnson & Johnson (JNJ) has filed two supplemental biologics license applications (sBLA) for its drug Tremfya, seeking expanded use in pediatric patients for moderate-to-severe plaque psoriasis and active juvenile psoriatic arthritis [1][3] Company Summary - Tremfya is an IL-23 inhibitor already approved for adult patients with plaque psoriasis and active psoriatic arthritis in multiple countries, including the United States and the EU [2] - Tremfya generated sales of $2.7 billion in the first nine months of 2024, reflecting a year-over-year increase of 21.6%, driven by strong market growth and share gains [4] - J&J anticipates Tremfya to become a $5 billion product, particularly with approvals for inflammatory bowel disease (IBD) conditions [7] Product Development - The sBLA for plaque psoriasis is based on data from the phase III PROTOSTAR study in pediatric patients, while the juvenile psoriatic arthritis filing relies on pharmacokinetic extrapolation from adult studies [3] - Tremfya was approved by the FDA for moderately to severely active ulcerative colitis (UC) in September 2023 and is under review in the EU for the same condition, as well as for Crohn's disease (CD) [6] Market Dynamics - There has been an increase in gastrointestinal disorders like UC and CD, driven by genetic, environmental, and lifestyle factors, which is boosting demand for IBD treatments [8] - Major competitors in the IBD market include AbbVie, Eli Lilly, Pfizer, Novartis, Merck, Sanofi, Gilead, and Amgen, all of which are developing new therapies with novel mechanisms of action [9] Competitive Landscape - AbbVie expects its immunology drugs Skyrizi and Rinvoq to double sales in IBD indications in 2024, supported by recent acquisitions of smaller biotech firms [10] - Lilly's new drug Omvoh has been approved for UC, and it has filed for CD in multiple regions, while also acquiring Morphic Therapeutics for IBD treatment [11] - Merck and Roche have made strategic acquisitions to enhance their IBD pipelines, focusing on novel therapies [12][13]

Core Insights - Johnson & Johnson has submitted two supplemental Biologics License Applications (sBLAs) to the FDA for TREMFYA® (guselkumab) to treat children aged 6 and older with moderate-to-severe plaque psoriasis and children aged 5 and older with active juvenile psoriatic arthritis [1][2] - The submissions are based on data from various Phase 3 studies, including the PROTOSTAR study for pediatric plaque psoriasis and extrapolated data from adult studies for juvenile psoriatic arthritis [1][4][5] - The company emphasizes its commitment to addressing the treatment gap for children and adolescents suffering from these conditions, highlighting the debilitating impact of visible skin diseases on this demographic [1][3] Company Overview - TREMFYA® is the first approved monoclonal antibody that selectively targets the p19 subunit of IL-23, a key driver of immune-mediated diseases like plaque psoriasis and psoriatic arthritis [1][6] - Johnson & Johnson maintains exclusive worldwide marketing rights for TREMFYA®, which is already approved for adult patients in multiple countries [6][9] Clinical Study Details - The PROTOSTAR study is a Phase 3 trial evaluating the efficacy, safety, and pharmacokinetics of TREMFYA® in pediatric patients with chronic plaque psoriasis, with co-primary endpoints including Investigator's Global Assessment (IGA) and PASI 75 at Week 16 [4] - The VOYAGE studies assessed TREMFYA® in adults with moderate to severe plaque psoriasis, focusing on achieving clear or almost clear skin and significant improvement in psoriasis severity [4][5] - The DISCOVER studies evaluated TREMFYA® in adults with active psoriatic arthritis, measuring the response rate at Week 24 [5]

Core Insights - Biocon Biologics Ltd has received FDA approval for YESINTEK™ (Ustekinumab-kfce), a biosimilar to Stelara® (Ustekinumab) [1][2] - YESINTEK™ is indicated for the treatment of Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis [2] Company Developments - The company had previously announced a settlement and licensing agreement with Janssen Biotech Inc., Janssen Sciences Ireland, and Johnson & Johnson to commercialize YESINTEK™ in the U.S. by February 22, 2025, following FDA approval [2]

Allocating the largest proportion of your dividend portfolio to Johnson & Johnson (NYSE: JNJ ) (NEOE: JNJ:CA ) can help you to effectively reduce the volatility of your investment portfolio, serving as a strategic defensive move toI specialize in constructing investment portfolios aimed at generating additional income through dividends. My focus lies on identifying companies with significant competitive advantages and strong financials that can provide you with an attractive Dividend Yield and Dividend Grow ...

Checking a company's vital signs before investing in its stock for dividend income is essential. If the underlying company isn't financially healthy, its dividend probably won't last very long.That won't be a problem with Johnson & Johnson (JNJ 0.39%) and Medtronic (MDT -0.53%). They're healthy companies that should continue to pay durable dividends in the decades ahead, making them great income investments. As healthy as it getsJohnson & Johnson is among the world's healthiest companies. The healthcare gia ...

Johnson & Johnson (JNJ) announced that it has submitted a regulatory filing with the FDA seeking approval for the use of a subcutaneous (SC) induction regimen of its blockbuster immunology medicine Tremfya (guselkumab) in ulcerative colitis (UC) indication. The FDA recently approved Tremfya to treat adults with moderately to severely active UC as both an induction and maintenance therapy. However, the induction dose of the drug can only be administered as an intravenous (IV) therapy. The maintenance dose of ...

Whether you prefer growth stocks, value stocks, dividend stocks, or a mixture of investments in your portfolio, price should only be one factor you consider when determining which businesses to add.Dividends can be a great way to increase your returns with time while giving you extra capital to reinvest or keep in your portfolio. These kinds of stocks can be found across many different sectors and industries.If you're looking for two top dividend stocks to consider for your portfolio and have $500 available ...

Join iREIT® on Alpha today to get the most in-depth research that includes REITs, mREIT, Preferreds, BDCs, MLPs, ETFs, Builders, and Asset Managers. Our iREIT® Tracker provides data on over 250 tickers with our quality scores, buy targets, and trim targets.When it comes to Dividend Elite’s, at the top of the hierarchy are Dividend Kings. Dividend Kings are defined as companies that have increased their dividend for 50+ consecutive years.Brad, along with HOYA Capital, lead the investing group iREIT®+HOYA Cap ...

POLAND - 2024/11/17: In this photo illustration, the AbbVie company logo is seen displayed on a ... [+] smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesGiven its better prospects, we believe that AbbVie stock (NYSE: ABBV) is currently a better pharmaceutical pick over Johnson & Johnson stock (NYSE: JNJ). Both AbbVie and J&J trade at 15x forward expected earnings. However, we think that the new drugs that are gaining market ...